The Sputnik-V single-dose vaccine showed 94 percent effectiveness, with the scientists saying, “There is no obvious benefit of using a second dose in previously infected people.”
Sputnik V developers claimed in June that the vaccine was around 90 percent effective against the highly contagious Delta variant.
One day after scientists announced that mRNA vaccines were effective against the Delta variant of Covid-19, a single-dose variant of the Russian Sputnik-V vaccine showed 94 percent effectiveness in recovered Covid-19 patients . Scientists said there was no apparent benefit in using a second dose on previously infected people.
However, they added, “The second dose further increases antibody and neutralizing capacity.”
The Study published in the journal Science Direct reported that 94 percent of participants developed spike-specific antibodies 21 days after receiving their first dose of vaccine. The study was conducted among medical personnel in Argentina.
“A single dose of Sputnik-V produces higher levels of antibodies and a higher capacity for virus neutralization in previously infected people than in new people who received the full two doses,” the researchers said.
Earlier, a study by the AIG hospitals in Hyderabad had also claimed that a single dose of the vaccine is sufficient for Covid-recovered patients due to their robust antibody response. The study was conducted on 260 healthcare workers who received the Covishield vaccine between January 16 and February 5.
Sputnik V has received emergency approval in India.
Sputnik V developers claimed in June that the vaccine was around 90 percent effective against the highly contagious Delta variant. Denis Logunov, deputy director of Moscow’s Gamaleya Institute, which developed Sputnik V, said the effectiveness number of the Delta variant was calculated based on digital medical and vaccine records, the RIA reported.
Sputnik V is the third vaccine used in India’s massive vaccination campaign after domestic Covishield from the Serum Institute of India and Bharat Biotechs Covaxin. While Sputnik Light was approved for emergency use in Russia in May with an effectiveness rate of 79.4 percent, discussions are currently underway about issuing an emergency approval in India.
ALSO READ | Dr. Reddys is partnering with vaccine freezer manufacturer for the launch of Sputnik V in India
The vaccine uses the genetic instructions from SARS-CoV-2 to build the spike protein and stores the information in the double-stranded DNA. The vaccine was developed from adenoviruses, a type of virus that causes colds. Researchers added the gene for the Covid-Spike protein to two adenoviruses and manipulated them to enter affected cells. The Sputnik-V is inspired by the adenovirus used by Johnson & Johnson to develop a vaccine against Ebola.
Click here for IndiaToday.in’s full coverage of the corona pandemic.
एक टिप्पणी भेजें